摘要
目的:观察吉非替尼(Gefitinib,ZD1839)治疗国人非小细胞肺癌的疗效及毒副作用。方法:自2003年4月至 2004年2月用吉非替尼250mg,每日口服,治疗失去手术机会及放化疗无效的非小细胞肺癌患者64例。结果:64例患者均可 评价,获得CR4例(6.25%),PR10例(15.63%),有效患者共14例(21.88%);SD32例(50%),其中持续时间≥24周者28 例;故临床获益率为65.63%[(4+10+28)/64];PD18例(28.12%)。与药物相关的不良反应依次为:皮疹32例(50%),恶 心16例(25%),腹泻14例(21.88%),皮肤干燥8例(12.5%),乏力5例(7.81%),其它如发热、口腔溃疡及关节痛等副反应 发生率均<5%。实验室指标未发现异常。结论:吉非替尼治疗国人晚期非小细胞肺癌有效,毒副反应少,患者耐受性好,值得 推广采用。
Objective:To observe the efficacy and drug-related toxicity of Gefitinib(ZD1839) in the treatment of advanced non-small cell lung cancer.Methods:Sixty-four non-small cell lung cancer patients who were unsuitable for surgical treatment,with poor response to chemoradiation were treated from Apr.2003 to Feb.2004.Gefitinib(ZD1839) was given,as a single drug,at a dose of 250mg per day orally.Results:Among these 64 patients,complete response 4(6.25%),partial response 10(15.63%),stable disease 32(50%),in which the stable persistence time of 28 patients exceeds 24 weeks,clinical benefit response 65.63%[(4+10+28)/64],progressive disease 18(28.12%).The drug-related adverse reactions are skin rash 32(50%),nausea 16(25%),diarrhea 14(21.88%),xerosis cutis 8(12.5%),fatigue 5(7.81%).The rates of adverse reactions such as fever,dental ulcer and arthralgia are below 5%.The breadboard index is normal.Conclusion:Gefitinib(ZD1839) is an effective drug in the treatment of patients with non-small cell lung cancer. The toxicity can be well acceptable.
出处
《临床肿瘤学杂志》
CAS
2005年第1期4-7,共4页
Chinese Clinical Oncology
